| 2025-12-29 |
详情>>
内部人交易：
Seshadri Vishwas股份减少25000.00股
|
| 2025-11-12 |
详情>>
股本变动：
变动后总股本5419.14万股
|
| 2025-11-12 |
详情>>
业绩披露：
2025年三季报(累计)每股收益1.76美元,归母净利润9164.30万美元,同比去年增长268.33%
|
| 2025-11-12 |
财报披露：
美东时间 2025-11-12 盘前发布财报
|
| 2025-08-14 |
详情>>
业绩披露：
2025年中报每股收益1.89美元,归母净利润9680.40万美元,同比去年增长500.48%
|
| 2025-05-15 |
详情>>
业绩披露：
2025年一季报每股收益-0.24美元,归母净利润-1202.9万美元,同比去年增长61.91%
|
| 2025-04-09 |
股东大会：
将于2025-05-19召开股东大会
会议内容 ▼▲
- 1.To elect Mark J. Alvino, Faith L. Charles, and Donald A. Wuchterl as Class 3 directors to hold office for a term of three years and until their successors are elected and qualified;
2.To approve, on an advisory basis, the compensation of the Company’s named executive officers;
3.To ratify the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2025.
|
| 2025-03-20 |
详情>>
业绩披露：
2024年年报每股收益-1.55美元,归母净利润-6373.4万美元,同比去年增长-17.62%
|
| 2024-11-14 |
详情>>
业绩披露：
2024年三季报(累计)每股收益-1.41美元,归母净利润-5444.1万美元,同比去年增长-44.8%
|
| 2024-11-12 |
股东大会：
将于2024-12-20召开股东大会
会议内容 ▼▲
- 1.To approve an increase in the number of shares of Common Stock reserved for issuance under the Second Amended and Restated Abeona Therapeutics Inc. 2023 Equity Incentive Plan from 3,200,000 to 8,400,000 shares of Common Stock.
2.To consider and vote upon an adjournment of the Special Meeting, if necessary, to solicit additional proxies if there are not sufficient votes in favor of Proposal No. 1.
|
| 2024-08-12 |
详情>>
业绩披露：
2024年中报每股收益-0.72美元,归母净利润-2417.2万美元,同比去年增长6.17%
|
| 2024-05-15 |
详情>>
业绩披露：
2024年一季报每股收益-1.16美元,归母净利润-3157.8万美元,同比去年增长-246.74%
|
| 2024-04-23 |
复牌提示：
2024-04-22 16:01:00 停牌，复牌日期 2024-04-22 16:35:00
|
| 2024-03-19 |
股东大会：
将于2024-04-24召开股东大会
会议内容 ▼▲
- 1.To elect Vishwas Seshadri and Leila Alland as Class 2 directors to hold office for a term of three years and until their successors are elected and qualified;
2.To approve an increase in the number of shares reserved for issuance under the Amended and Restated Abeona Therapeutics Inc. 2023 Equity Incentive Plan from 1,700,000 to 3,200,000 shares;
3.To approve, on an advisory basis, the compensation of the Company’s named executive officers;
4.To ratify the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024.
|
| 2024-03-18 |
详情>>
业绩披露：
2023年年报每股收益-2.53美元,归母净利润-5418.8万美元,同比去年增长-24.63%
|
| 2023-11-13 |
详情>>
业绩披露：
2023年三季报(累计)每股收益-1.89美元,归母净利润-3759.7万美元,同比去年增长-3.41%
|
| 2023-08-08 |
详情>>
业绩披露：
2023年中报每股收益-1.48美元,归母净利润-2576.1万美元,同比去年增长13.91%
|
| 2023-04-13 |
股东大会：
将于2023-05-17召开股东大会
会议内容 ▼▲
- 1.To elect Michael Amoroso and Christine Silverstein as Class 1 directors to hold office for a term of three years and until their successors are elected and qualified;
2.To approve the Abeona Therapeutics Inc. 2023 Equity Incentive Plan;
3.To approve, on an advisory basis, the compensation of the Company’s named executive officers;
4.To ratify the appointment of Whitley Penn LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2023.
|
| 2022-07-11 |
股东大会：
将于2022-08-17召开股东大会
会议内容 ▼▲
- 1.To elect Mark J. Alvino, Faith L. Charles and Donald A. Wuchterl as Class 3 directors to hold office for a term of three years and until their successors are elected and qualified;
2.To approve an amendment to the Abeona Therapeutics Inc. 2015 Equity Incentive Plan to increase the number of shares of our Common Stock authorized for issuance thereunder from 720,000 to 1,440,000 shares;
3.To approve, on an advisory basis, the compensation of the Company’s named executive officers;
4.To consider an advisory vote on the frequency of future advisory votes on the compensation of the Company’s named executive officers;
5.To ratify the appointment of Whitley Penn LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2022.
|
| 2022-07-05 |
详情>>
拆分方案：
每25.0000合并分成1.0000股
|
| 2022-05-12 |
股东大会：
将于2022-06-14召开股东大会
会议内容 ▼▲
- 1.To approve an amendment to the Restated Certificate of Incorporation of the company to effect a reverse stock split of our common stock at a ratio to be determined by the Board within a range of one-for-10 to one-for-80 (or any number in between), without reducing the authorized number of shares of our common stock, to be effected in the sole discretion of the Board at any time within one year of the date of the Special Meeting without further approval or authorization of our stockholders;
2.To consider and vote upon an adjournment of the Special Meeting, if necessary, to solicit additional proxies if there are not sufficient votes in favor of Proposal No. 1.
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2021-04-09 |
股东大会：
将于2021-05-26召开股东大会
会议内容 ▼▲
- 1.To elect Steven H. Rouhandeh and Michael Amoroso as Class 2 Directors to hold office for a term of three years and until their successors are elected and qualified;
2.To vote on a proposal to amend our Restated Certificate of Incorporation to de-classify our Board of Directors so that all directors are elected annually;
3.To ratify the appointment of Whitley Penn LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2021.
|
| 2020-04-10 |
股东大会：
将于2020-05-20召开股东大会
会议内容 ▼▲
- 1.To elect each of Christine Berni Silverstein and Todd Wider, M.D. as Class 1 Directors to hold office for a term of three years and until their successors are elected and qualified;
2.To approve an amendment to the Abeona Therapeutics Inc. 2015 Equity Incentive Plan to increase the number of shares of our Common Stock authorized for issuance thereunder from 10,000,000 to 18,000,000 shares;
3.To approve the Company’s non-employee director compensation plan;
4.To ratify the appointment of Whitley Penn LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2020;
5.To vote on a shareholder proposal included in the proxy, if properly presented at the Annual Meeting.
|
| 2019-04-11 |
股东大会：
将于2019-05-28召开股东大会
会议内容 ▼▲
- 1.To elect Mark Alvino, Stefano Buono and Joao Siffert, M.D. as Class 3 Directors to hold office for a term of three years and until their successors are elected and qualified;
2.To approve, on an advisory basis, the compensation of the Company’s named executive officers;
3.To ratify the appointment of Whitley Penn LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2019;
4.To transact such other business as may properly come before the Meeting or any adjournment or postponement thereof.
|
| 2018-04-10 |
股东大会：
将于2018-05-10召开股东大会
会议内容 ▼▲
- 1.To elect the two Class 2 Directors named in the accompanying proxy statement to hold office for a term of three years and until their successors are elected and qualified.
2.To ratify the appointment of Whitley Penn LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2018.
|
| 2017-04-11 |
股东大会：
将于2017-05-15召开股东大会
会议内容 ▼▲
- 1.To elect one Class 1 Director to hold office for a term of three years and until his successor is elected and qualified.
2.To amend the Company’s 2015 Equity Incentive Plan to increase the number of shares of common stock reserved for issuance thereunder.
3.To ratify the appointment of Whitley Penn LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2017.
4.To transact such other business as may properly come before the Meeting or any postponements or adjournments thereof.
|
| 2016-04-06 |
股东大会：
将于2016-05-12召开股东大会
会议内容 ▼▲
- 1.To elect three Class 3 Directors to hold office for a term of three years and until their successors are elected and qualified.
2.To consider an advisory vote on the compensation of the Company’s named executive officers.
3.To consider an advisory vote on the frequency of future advisory votes on the compensation of the Company’s named executive officers.
4.To amend the Company’s 2015 Equity Incentive Plan to increase the number of shares of common stock reserved for issuance thereunder.
5.To ratify the appointment of Whitley Penn LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2016.
6.To transact such other business as may properly come before the Meeting or any postponements or adjournments thereof.
|